Replies to post #82807 on $heff's $tation of $tocks & $olid DD

[$heff]

AVNR..$6.09 is on watch. More comments from the recent transcripts.

"The outlook for our future is bright and we are focused on strategies that will lead to solid long-term enterprise growth. From now through the end of the calendar year, we’ll have continued growth in our NUEDEXTA business. We’ll have full PRISM II Alzheimer’s in PBA dataset available later this year.

We’ll have the Phase II proof-of-concept data read out in agitation and levodopa-induced dyskinesia study in Parkinson patients. We’ll have the first patient in, in our first AVP-786 study in adjunctive therapy for major depressive disorder and finally, we’ll have the AVP-825 PDUFA date followed by the launch of AVP-825 in the first half of calendar 2015. With that summary of the milestones and catalysts, I’d now like to open up the call for questions. "